Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Lansoprazole

Lansoprazole

Lansoprazole is a proton pump inhibitor medication used to treat and prevent stomach ulcers, gastroesophageal reflux disease (GERD), and other conditions caused by excess stomach acid.
It works by reduceing the production of acid in the stomach.
Lansoprazole is available by prescript ion and over-the-counter, and is generallly considered safe and effective when used as directed.
Patients should consult their healthcare provider before starting or stopping Lansoprazole or any other medication.

Most cited protocols related to «Lansoprazole»

1
Pediatric Asthma and Acid Reflux
Cited 10 times
The Study of Acid Reflux in Children with Asthma (SARCA) was a randomized (allocation ratio 1:1) double masked, placebo-controlled, parallel clinical trial designed to evaluate the effectiveness of lansoprazole (Prevacid ®, TAKEDA Pharmaceuticals North America) for treatment of asthma in children (clinicaltrial.gov NCT00442013). The study was conducted at 19 American Lung Association's Asthma Clinical Research Center (ALA-ACRC) sites from to April 2007 to April 2011. The study was approved by the institutional review board at each center, and the legal guardians signed informed consent statement and the participants signed assent statement according to local regulatory policy.
Children were randomly assigned to receive either lansoprazole (15 mg daily for children < 30 kg; 30 mg daily for children ≥ 30 kg) or a matching placebo. A permuted block treatment assignment schedule stratified by clinical center was used. Treatment assignments were masked throughout the study. After the screening and randomization visits, participants returned to the clinical centers for assessments every 4 weeks for 24 weeks. Throughout the study children kept daily diaries to record morning peak expiratory flow, asthma symptoms, nocturnal awakenings, use of short-acting β-agonists (excluding routine use before exercise), oral corticosteroid use, and unscheduled health care visits for asthma symptoms. Ambulatory esophageal pH monitoring prior to randomization was conducted in a subgroup of children who agreed to the procedure at 13 clinical centers with the capability of doing pH probe studies for the study. Participants were paid, on average, ($ ) for each study visit.
Holbrook J.T., Wise R.A., Gold B.D., Blake K., Brown E.D., Castro M., Dozor A.J., Lima J., Mastronarde J.G., Sockrider M, & Teague W.G. (2012). Randomized Clinical Trial of Lansoprazole for Poorly Controlled Asthma in Children: The American Lung Association Asthma Clinical Research Centers. JAMA : the journal of the American Medical Association, 307(4), 373-381.
Publication 2012
Adrenal Cortex Hormones agonists Asthma Central American People Child Ethics Committees, Research Exhaling Gastroesophageal Reflux Disease Lansoprazole Legal Guardians Lung Pharmaceutical Preparations Placebos Prevacid Treatment Protocols
2
PPI and H2RA Usage in Taiwan
Cited 8 times
The PPIs available in Taiwan between 2000 and 2013 and considered in this study included esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. Patients' prescription histories of PPIs and H2RAs were included in this study. Use of medications was defined as prescription any of the medications studied in this work before the index date. No use of medication was defined as no history of prescription of any of the medications studied in this work before the index date.
Cheng K.C., Liao K.F., Lin C.L, & Lai S.W. (2017). Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan. Frontiers in Pharmacology, 8, 481.
Full text: Click here
Publication 2017
Esomeprazole Lansoprazole Omeprazole Pantoprazole Patients Pharmaceutical Preparations Prepulse Inhibition Prescription Drugs Rabeprazole
3
Febuxostat and Allopurinol in Gout Management
Cited 6 times
Subjects aged 18 to 85 years with a diagnosis of gout fulfilling American Rheumatology Association preliminary criteria [36 (link)] and sUA ≥ 8.0 mg/dL were eligible for enrollment. Subjects were enrolled at 324 sites in the United States. Institutional Review Board approval was obtained, and all subjects provided written informed consent and Health Insurance Portability and Accountability Act authorization prior to any study-related procedure. At least 35% of subjects enrolled were to have mild or moderate renal impairment, defined as baseline estimated creatinine clearance (eCLcr) of 60 to 89 ml/minutes or 30 to 59 ml/minutes, respectively, calculated by the Cockcroft-Gault formula corrected for ideal body weight [37 (link),38 (link)]. Subjects successfully completing either of two previously reported long-term, open-label febuxostat [13 (link)] or febuxostat/allopurinol [14 (link)] extension studies were also eligible for enrollment.
Exclusion criteria included: secondary hyperuricemia (for example, due to myeloproliferative disorder); xanthinuria; severe renal impairment (eCLcr <30 ml/minutes [37 (link),38 (link)]); alanine aminotransferase and aspartate aminotransferase values >1.5 times the upper limit of normal; consumption of more than 14 alcoholic drinks per week or a history of alcoholism or drug abuse within five years; or a medical condition that, in the investigator's opinion, would interfere with treatment, safety, or adherence to the protocol.
Subject screening evaluations included: physical examination and vital signs; medical history, a pre-specified CV history/risk form; laboratory tests (sUA, complete chemistry panel, hematology, urinalysis, and, for women, pregnancy test); echocardiogram; assessment for tophi and gout flare; and concomitant medication use. With the exception of tophus assessment, these elements, along with compliance, were repeated at bimonthly visits during the six-month treatment period. sUA was blinded after baseline determination at Day-4.
An Interactive Voice Response System was utilized by site personnel during screening visits to initiate double-blind randomization. Subjects were randomized 1:1:1 on Day 1 to receive daily febuxostat 40 mg, febuxostat 80 mg, or allopurinol (Apotex; Weston, FL, USA). Randomization was stratified by baseline renal function and prior completion of either of two open-label extension trials [13 (link),14 (link)]. Among subjects randomized to allopurinol, those with normal renal function or mild renal impairment received 300 mg daily, and those with moderate renal impairment received 200 mg.
During a 30-day washout period for subjects receiving prior ULT, and throughout the subsequent six-month treatment period for all subjects, prophylaxis for gout flares was given either as colchicine, 0.6 mg daily (West-Ward Pharmaceutical Corporation, Eatontown, NJ, USA) or naproxen, 250 mg twice daily (West-Ward Pharmaceutical Corporation). All subjects receiving naproxen prophylaxis also received lansoprazole 15 mg daily (Takeda Global Research & Development Center, Inc., Deerfield, IL, USA). Choice of prophylaxis regimen was made by the investigator and subject, taking into account prior drug tolerance and prophylaxis experience. In addition, subjects with eCLcr <50 ml/minute were not to receive naproxen. Gout flares were regarded as expected gout manifestations rather than as AEs.
Becker M.A., Schumacher H.R., Espinoza L.R., Wells A.F., MacDonald P., Lloyd E, & Lademacher C. (2010). The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Research & Therapy, 12(2), R63.
Full text: Click here
Publication 2010
Alcoholic Beverages Alcoholic Intoxication, Chronic Allopurinol Aspartate Transaminase Colchicine Comprehensive Metabolic Panel Creatinine D-Alanine Transaminase Diagnosis Drug Abuse Echocardiography Ethics Committees, Research Febuxostat Gout Hyperuricemia Ideal Body Weight Kidney Lansoprazole Myeloproliferative Disorders Naproxen Pharmaceutical Preparations Physical Examination Pregnancy Tests Renal Insufficiency Safety Signs, Vital Treatment Protocols Urinalysis Woman
4
Vonoprazan vs. Lansoprazole for Erosive Esophagitis
Cited 5 times
The initial study was an 8‐week randomised, double‐blind, multicentre, parallel‐group, active‐controlled comparison study designed to verify the non‐inferiority of vonoprazan 20 mg to lansoprazole 30 mg in patients with endoscopically confirmed EE [Los Angeles (LA) Classification Grades A–D]. Patients who achieved endoscopically healed EE by week 8 in the comparison study were re‐randomised into a second sequential randomised, single‐blind, multicentre, parallel‐group, long‐term maintenance study to evaluate the safety and efficacy of vonoprazan 10 or 20 mg in patients with healed EE.
The comparison study was conducted in 39 sites in Japan between October 2011 and August 2012, and the sequential long‐term maintenance study was conducted at the same sites between November 2011 and July 2013. The studies were approved by the Institutional Review Board at each study site. They were conducted in accordance with the Declaration of Helsinki and the ICH Harmonised Tripartite Guideline for Good Clinical Practice, and all patients provided written informed consent for the comparison study as well as the long‐term maintenance study. The studies were registered at ClinicalTrials.gov with the identifiers NCT01452698 and NCT01452776.
In the comparison study, following a 3–7 day screening period, patients were randomised to treatment with vonoprazan 20 mg or lansoprazole 30 mg, both administered orally once daily after breakfast, for 2, 4 or 8 weeks. Subjects completed double‐blind treatment after 2, 4 or 8 weeks when healing was endoscopically confirmed. If the EE was not healed after completing the 8‐week treatment period, the patient received vonoprazan 40 mg for 4 or 8 weeks in a non‐blinded manner.
Subjects with healed EE at week 2, 4 or 8 in the comparison study were randomised 1:1 to receive vonoprazan 10 or 20 mg orally once daily after breakfast for 52 weeks in the sequential long‐term maintenance study after providing additional informed consent.
Ashida K., Sakurai Y., Hori T., Kudou K., Nishimura A., Hiramatsu N., Umegaki E, & Iwakiri K. (2015). Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 43(2), 240-251.
Publication 2015
Ethics Committees, Research Lansoprazole Patients Safety Vonoprazan
5
Gastric Cancer Eradication Protocol
Cited 5 times
The present hospital-based case-control study included 50 patients who had undergone ER for intestinal-type mucosal gastric cancer (Group DYS) and 25 chronic gastritis patients (control) recruited at Asahikawa Medical College Hospital. Group DYS was divided into 2 subgroups matched by age and sex: the H. pylori-eradicated group (eradicated group, n=25) and the H. pylori un-eradicated group (persistent group, n=25). The control was similarly matched to Group DYS cases by age and sex. Mucosal gastric cancer was defined as any cancer in which invasion was limited to the mucosa.26 In all patients, biopsy specimens were taken to assess H. pylori infection, two each from the greater curvature of the antrum and the greater curvature of the corpus. The presence of H. pylori status was determined by a positive result for either or both Wartin-Starry staining or H. pylori culture. For eradication, patients were treated with lansoprazole (30 mg), amoxicillin (750 mg), and clarithromycin (400 mg), each taken twice daily for 1 week. All patients in the eradicated group underwent ER for their mucosal cancer and then received treatment for H. pylori. Following eradication, all patients were followed up with an endoscopic examination 1 year later. At the follow-up endoscopy, successful eradication was documented by the above methods. In patients from the eradicated group and control, clearance of H. pylori was confirmed by negative results by both Wartin-Starry staining and H. pylori culture at a follow-up endoscopy. Written informed consent was obtained from the patients, and the Ethics Committee of Asahikawa Medical University gave its approval for the study.
Watari J., Moriichi K., Tanabe H., Kashima S., Nomura Y., Fujiya M., Tomita T., Oshima T., Fukui H., Miwa H., Das K.M, & Kohgo Y. (2011). Biomarkers predicting development of metachronous gastric cancer after endoscopic resection: an analysis of molecular pathology of Helicobacter pylori eradication. International Journal of Cancer. Journal International du Cancer, 130(10), 2349-2358.
Publication 2011
Amoxicillin Antral Biopsy Clarithromycin Endoscopy Endoscopy, Gastrointestinal Ethics Committees Gastric Cancer Gastritis Helicobacter pylori Infection Intestinal Cancer Intestinal Mucosa Lansoprazole Malignant Neoplasms Mucosa, Gastric Mucous Membrane Patients Stars, Celestial

Most recents protocols related to «Lansoprazole»

1
Dental Implant Failure in PPI Users
The cohort included 687 patients and 2971 dental implants. The study group (PPIs users) comprised 17.3% (119) individuals and 18.7% (555) implants. Only subjects who continuatively used one of the PPI (ATC code A02BC, i.e., omeprazole, pantoprazole, lansoprazole, dexlansoprazole, esomeprazole, rabeprazole, dexrabeprazole, or a combination of these)) for at least 1 year were included in the study group.
The remaining cohort (82.7% (568) individuals and 81.3% (2416) implants) served as control.
All the implants used were two-p, iece, internal hex, rough surface titanium (Tapered ® Screw-Vent Implant System, Zimmer Dental, (Warsaw, IN, USA); Lance®, MIS, (Bar Lev Industrial Park BAR-LEV, 2015600 Israel); MPI®, Ditron Dental, 2 Haofe St. South ind. Zone P.O.B 5010 Ashkelon 7815001 Israel). All treatments were performed by experienced oral and maxillofacial surgeons and prosthodontists. The study protocol was approved by the ethics committee of the Rabin Medical Center, Campus Beilinson, Israel (0674-19rmc). The present script complies with the STROBE guidelines [15 (link)]. Dental records of all individuals included were extracted and manually screened twice by 2 examiners (DM and LC).
The following information was collected: age, gender, physical status, systemic diseases, HbA1C values before and after implant-supported prosthesis delivery in cases of diabetes mellitus, smoking, implant location, number of implants per individual, bone augmentation, implant brand, length and width, and EIF.
EIF was defined as implant removal within a period of up to 12 months from loading.
Masri D., Retzkin N., Luís Scombatti de Souza S., Slutzkey G.S., Tagger-Green N., Naishlos S, & Chaushu L. (2023). The Effect of Proton Pump Inhibitors on Early Implant Failure A Retrospective Cohort Study. Medicina, 59(2), 402.
Full text: Click here
Publication 2023
Artificial Implants Bones Dental Health Services Dexlansoprazole Dexrabeprazole Diabetes Mellitus Esomeprazole Ethics Committees Implant, Dental Lansoprazole Obstetric Delivery Omeprazole Oral and Maxillofacial Surgeons Pantoprazole Patients Physical Examination Prosthodontists Rabeprazole Titanium
2
Retrospective Analysis of 13C-urea Breath Test
We performed a retrospective analysis from the database of 13C‐urea breath test (UBT) in Fu Jen Catholic University Hospital from 1 April 2021 to 31 December 2021. Patients were deemed to have H. pylori infection through a positive rapid urease test, H. pylori stool antigen test, urea breath test (UBT), or pathology report showing H. pylori in tissues. Those with only positive anti‐H. pylori IgG or those referred from other medical facilities for H. pylori eradication without records of the diagnostic modalities were excluded. Patients with H. pylori infection and receiving first‐line therapy were recruited and divided into two groups according to their anti‐H. pylori regimen: the VAC‐7 group (vonoprazan 20 mg + amoxicillin 1000 mg + clarithromycin 500 mg twice daily for 7 days) and the S‐14 group (PPI [lansoprazole 30 mg/rabeprazole 20 mg/pantoprazole 40 mg] + amoxicillin 1000 mg twice daily for 7 days, followed by the same PPI + clarithromycin 500 mg + metronidazole 500 mg twice daily for 7 days).
Chiu Y., Lee F., Kuo C., Lin Y., Liang K., Tseng L., Chen Y, & Chang C. (2023). Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy. JGH Open: An Open Access Journal of Gastroenterology and Hepatology, 7(2), 105-109.
Full text: Click here
Publication 2023
Amoxicillin anti-IgG Antigens Breath Tests Clarithromycin Diagnosis Fecal Occult Blood Test Helicobacter pylori Infection Lansoprazole Metronidazole Pantoprazole Patients Rabeprazole Roman Catholics Therapeutics Tissues Treatment Protocols Urea Urease Vonoprazan
3
Replacing Omeprazole with Alternative PPIs
Since Omeprazole is known to be over prescribed and has one of the largest number of interactions observed in our study (see tables S3 and S9), we simulate the replacement of Omeprazole with alternative PPIs in observed DDI cases. We use the ATC drug classification system that describes chemical subgroups containing drugs that could, in principle, be interchanged for the treatment of the same disease to identify alternatives. Thus, as proof of concept, we focus on the PPI subgroup: Omeprazole, Pantoprazole, Esomeprazole, Lansoprazole, and Rabeprazole. We then replace, in each situation, Omeprazole with the alternative that avoids interactions with other drugs and recalculate the previously described risk measures.
Sánchez-Valle J., Correia R.B., Camacho-Artacho M., Lepore R., Mattos M.M., Rocha L.M, & Valencia A. (2023). Analysis of electronic health records from three distinct and large populations reveals high prevalence and biases in the co-administration of drugs known to interact. medRxiv.
Publication Preprint 2023
Drug Interactions Esomeprazole Lansoprazole Omeprazole Pantoprazole Pharmaceutical Preparations Rabeprazole
4
Evaluating TC and PPI Effects on EGFR-TKI Therapy
The TC and PPI period was calculated from the index date until the conclusion of the study.
Patients were divided into the following four groups: TC-/PPI-, TC + /PPI-, TC-/PPI + , and TC + /PPI + .

(1) The TC-/PPI- group consisted of patients who were neither on TC nor PPI therapy (control group).

(2) The TC + /PPI- group consisted of patients whose period of TC (doxycycline or minocycline) and EGFR-TKI therapy overlapped by at least 20% but were not on PPIs.

(3) The TC-/PPI + group consisted of patients whose period of PPI (esomeprazole, pantoprazole, rabeprazole, or lansoprazole) and EGFR-TKI therapy overlapped by at least 20% but were not on TCs.

(4) The TC + /PPI + group consisted of patients taking TCs and PPIs concomitantly with EGFR-TKI therapy, and both therapeutic regimens overlapped by at least 20%.

Hsieh H.H., Wu T.Y., Chen C.H., Kuo Y.H, & Hour M.J. (2023). Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study. BMC Cancer, 23, 151.
Full text: Click here
Publication 2023
Doxycycline EGFR protein, human Esomeprazole Lansoprazole Minocycline Pantoprazole Patients Prepulse Inhibition Rabeprazole Therapeutics Treatment Protocols
5
Gastric Function and PPI Therapy Assessment
The inclusion criteria were as follows:

Age > 18 years.

Determination of gastric function using serological testing.

PPI use for at least 3 months prior to evaluation. Therapy with PPI included the following generic and brand drugs: Omeprazole (Antra®, Omeprazen®, Mepral®, and Losec®), Esomeprazole (Nexium®, Lucen®, Axagon®, and Esopral®, Pantoprazole (Pantorc®, Pantopan®, Pantecta®, Peptazol®), Rabeprazole (Pariet®), and Lansoprazole (Zoton®, Limpidex®, and Lansox®).

The presence of symptoms attributed to gastroesophageal acid-related disease, for which patients were on PPI therapy; symptoms were assigned to the following categories: pain symptoms (including epigastric and abdominal pain); reflux symptoms (including heartburn, acid regurgitation, persistent hiccup, belching, sialorrhea, and globus pharynges); maldigestion symptoms (including nausea, bloating, flatulence, rumbling abdomen, bitter taste in the mouth, and aerophagia); otorhinolaryngological symptoms (including hoarseness, chronic laryngitis, coughing, glossitis, and pharyngitis); and chest/cardiac symptoms (including thoracic pain, tachycardia, extrasystoles, and dyspnea).

Russo M., Rodriguez-Castro K.I., Franceschi M., Ferronato A., Panozzo M.P., Brozzi L., Di Mario F., Crafa P., Brandimarte G, & Tursi A. (2023). Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers. International Journal of Molecular Sciences, 24(3), 2378.
Full text: Click here
Publication 2023
Abdomen Abdominal Pain Acids Aerophagy Antral Chest Chest Pain Dyspnea Esomeprazole Flatulence Generic Drugs Globus Sensation Glossitis Heart Heartburn Hoarseness Lansoprazole Laryngitis Nausea Nexium Omeprazole Oral Cavity Pain Pantoprazole Pariet Patients Pharmaceutical Preparations Pharyngitis Pharynx Premature Cardiac Complex Rabeprazole Sialorrhea Stomach Taste Therapeutics Zoton

Top products related to «Lansoprazole»

1
Lansoprazole by Merck Group
Sourced in United States, Germany, Italy, United Kingdom, India
Lansoprazole is a proton pump inhibitor (PPI) medication used to reduce stomach acid production. It works by blocking the enzyme responsible for acid secretion in the stomach, thus decreasing the amount of acid available to cause damage. Lansoprazole is used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders.
2
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
3
Omeprazole by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe
Omeprazole is a proton pump inhibitor (PPI) medication used to reduce gastric acid production. It is a colorless or slightly yellow crystalline powder. Omeprazole functions by inhibiting the H+/K+ ATPase enzyme system in the parietal cells of the stomach, thereby reducing the secretion of gastric acid.
4
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
5
Quercetin by Merck Group
Sourced in United States, Germany, Italy, India, Spain, United Kingdom, France, Poland, China, Sao Tome and Principe, Australia, Brazil, Macao, Switzerland, Canada, Chile, Japan, Singapore, Ireland, Mexico, Portugal, Sweden, Malaysia, Hungary
Quercetin is a natural compound found in various plants, including fruits and vegetables. It is a type of flavonoid with antioxidant properties. Quercetin is often used as a reference standard in analytical procedures and research applications.
6
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
7
Acetonitrile by Merck Group
Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia
Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.
8
Lansoprazole by Tokyo Chemical Industry
Sourced in Japan
Lansoprazole is a chemical compound used in laboratory settings. It is a proton pump inhibitor that is commonly used to reduce gastric acid production. The core function of lansoprazole is to inhibit the activity of the hydrogen-potassium adenosine triphosphatase enzyme system, which is responsible for the final step in gastric acid secretion.
9
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
10
Dexamethasone (dex) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.

More about "Lansoprazole"

Lansoprazole is a proton pump inhibitor (PPI) medication commonly used to treat and prevent stomach ulcers, gastroesophageal reflux disease (GERD), and other conditions caused by excessive stomach acid production.
It works by reducing the amount of acid produced in the stomach, allowing the esophagus and stomach lining to heal.
Lansoprazole is available by prescription and over-the-counter, and is generally considered safe and effective when used as directed.
Patients should consult their healthcare provider before starting or stopping Lansoprazole or any other medication.
When researching Lansoprazole, it's important to consider related terms and substances.
DMSO (Dimethyl Sulfoxide) is a common solvent used in Lansoprazole research, while Omeprazole is another PPI medication similar to Lansoprazole.
Formic acid, Quercetin, Methanol, and Acetonitrile may also be encountered in studies involving Lansoprazole.
Additionally, FBS (Fetal Bovine Serum) and Dexamethasone are frequently used in cell culture and in vitro experiments.
Optimizing Lansoprazole research can be greatly assisted by tools like PubCompare.ai, which use AI-driven data analysis to help researchers locate the best protocols and improve the reproducibility and accuracy of their studies.
By incorporating insights from the literature, pre-prints, and patents, PubCompare.ai can empower researchers to experince the future of research optimization and make more informed decisions about their Lansoprazole research.